Healthcare >> Analyst Interviews >> May 20, 2002
ALBERT RAUCH is an Analyst and head of healthcare equity research
at Ladenburg, Thalmann & Co., focusing on genomic, gene therapy
and protein synthesis stocks. He was previously with Wachovia
(formerly First Union), EVEREN Securities and A.G. Edwards. Prior
to becoming an Equity Research Analyst, Mr. Rauch was a Senior
Research Scientist with Pfizer and taught at the Wake Forest
University School of Medicine. A Chartered Financial Analyst, he
received a BS and an MS from the University of South Dakota, an
MBA from Rensselaer Polytechnic Institute and a PhD from Emory
University. Profile
cover for Ladenburg Thalmann?
Mr. Rauch: I focus on genomics, antibody therapeutics, and gene
therapy companies in the
